NCT03638843View on ClinicalTrials.gov

Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy - Part 2

NACompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 25, 2020

Primary Completion Date

July 8, 2021

Study Completion Date

July 8, 2021

Conditions
ObesityObesity, MorbidObesity; EndocrineBariatric Surgery Candidate
Interventions
PROCEDURE

Gastric mucosal devitalization

Gastric mucosal devitalization is an endoscopic procedure which uses argon plasma coagulation to result in selective damage to the gastric mucosa and submucosa.

Trial Locations (1)

21287

Johns Hopkins Medical Institutions, Baltimore

All Listed Sponsors
collaborator

Erbe USA Incorporated

OTHER

lead

Johns Hopkins University

OTHER

NCT03638843 - Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy - Part 2 | Biotech Hunter | Biotech Hunter